Literature DB >> 17485136

General practitioner assessment of stage and performance status in lung cancer patients at a population level: implications for prognosis and radiotherapy needs analyses.

S Tyldesley1, T W Roques, S Erridge.   

Abstract

BACKGROUND: Stage, weight loss, and performance status (PS) are important prognostic factors and eligibility factors for curative intent therapy for lung cancer patients. Details of stage, weight loss, and PS are often not collected until referral to a cancer specialist, and since not all patients are referred to cancer specialists these important variables are not well defined at a population level. PATIENTS AND METHODS: Data on stage, weight loss, PS and referral pattern were requested from general practitioners (GPs) on all lung cancer patients diagnosed between May and June of 2002 in the province of British Columbia, Canada. Outcomes were analyzed in relation to survival and referral to a cancer centre.
RESULTS: 395 patients were identified, and GP questionnaires were returned on 85% of the cases. Patients referred to a cancer centre shortly after diagnosis differed from those who were not referred. Patients who were not referred to a cancer centre consisted of two groups-patients with localized disease and good PS who tended to have a better survival than those who were referred, and patients with advanced disease and poor performance status who tended to have a worse survival than those who were referred. GP assessed stage and PS are prognostic factors for survival.
CONCLUSIONS: GP assessed stage and PS are prognostic factors for survival in lung cancer patients. The case mix of patients who are not referred to a cancer centre shortly after their diagnosis differs from those that are referred.

Entities:  

Mesh:

Year:  2007        PMID: 17485136     DOI: 10.1016/j.lungcan.2007.03.024

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  4 in total

1.  Squamous cell carcinoma of the lung with simultaneous metastases to peritoneum and skeletal muscle.

Authors:  Sung Heon Song; Yoon Jung Oh; Young Nam Kim; Ha Hun Song; Chang Won Ha
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

2.  Physician And Patient Barriers To Radiotherapy Service Access: Treatment Referral Implications.

Authors:  Sara Chierchini; Gianluca Ingrosso; Simonetta Saldi; Fabrizio Stracci; Cynthia Aristei
Journal:  Cancer Manag Res       Date:  2019-10-07       Impact factor: 3.989

Review 3.  Barriers to accessing radiation therapy in Canada: a systematic review.

Authors:  Caitlin Gillan; Kaleigh Briggs; Alejandro Goytisolo Pazos; Melanie Maurus; Nicole Harnett; Pamela Catton; David Wiljer
Journal:  Radiat Oncol       Date:  2012-10-12       Impact factor: 3.481

4.  Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.

Authors:  Jianxin Chen; Junhui Wang; Hai Lin; Yonghai Peng
Journal:  Med Sci Monit       Date:  2019-12-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.